A new US eye-area skincare formulation comes with a small company-reported evaluation, not evidence that topical cream corrects anatomical hollows.
What launched?
Galderma announced the US launch of an updated ALASTIN Restorative Eye Complex with TriHex+ on 26 October 2026. The product is intended for visible changes around the upper eyelid, lower eyelid and lateral eye area. The company describes a revised peptide-based formulation containing Octapeptide-45, acetyl tetrapeptide-2 and botanical ingredients in addition to existing components.
The announcement belongs in the new-product desk rather than the regulatory approvals desk. It is a skincare launch, and the material retrieved does not establish that it has undergone a prescription-drug approval process or that it replaces medical treatments.
What evidence did the company provide?
Galderma described a clinical evaluation involving 29 adults aged 35 to 70 with moderate-to-severe visible signs of eye-area aging. At week 12, investigator grading reportedly found a 30.13% improvement in crow’s-feet fine lines, 33.63% improvement in under-eye puffiness and 21.62% improvement in upper-eyelid fine lines, each with a reported P value below 0.0001.
Those percentages describe changes on study assessments, not a guaranteed reduction in wrinkles for individual consumers. The announcement does not provide sufficient information to establish an independently randomized or placebo-controlled design. A small evaluation can generate useful signals but is less persuasive than a well-controlled trial with published methods.
What is TriHex+?
The company says TriHex+ combines an existing peptide platform with Octapeptide-45 and is designed to support the skin’s structural proteins and hyaluronic-acid-related hydration. Mechanistic descriptions in promotional materials should be distinguished from direct clinical measurements of collagen, elastin or durable tissue remodeling.
Periorbital concerns are not interchangeable. Fine lines and surface hydration can be affected by topical products, whereas substantial tear-trough hollowing may reflect bone structure, fat distribution, ligament anatomy or skin laxity. No topical product should be described as an anatomical alternative to fillers or surgery without direct comparative evidence.
Availability and practical interpretation
Galderma says the new formulation will initially be sold in the United States through authorized healthcare providers and their online storefronts. Availability in India or other regions should not be assumed.
For Aesthetics.news, the useful story is how companies are positioning peptide-based products within the medical aesthetics ecosystem, alongside the need for rigorous study designs. Readers should interpret the company’s numerical results as preliminary product-specific evidence and discuss persistent eye-area concerns with an appropriately qualified clinician.
What independent testing would add
A future randomized, vehicle-controlled study could clarify how much of the observed change is attributable to the revised formula rather than moisturization, natural variation or expectations. Such a trial would ideally specify validated assessment scales, photographs under standardized lighting, independent graders and follow-up after product discontinuation. That would help clinicians and consumers compare a topical eye product with other skincare options without conflating improvements in surface appearance with changes in deep facial anatomy.
Original sources
Galderma official product announcement, 26 October 2026: https://www.galderma.com/news/galderma-launches-alastin-restorative-eye-complex-trihextm
Source / evidence limitation: Company-issued evidence; 29-person evaluation design not fully established; no independent comparative study verified.
Medical disclaimer
This article is published by Aesthetics.news for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment, and should not replace a consultation with a qualified healthcare professional. Treatments and outcomes may vary from person to person. Readers should seek advice from an appropriately qualified professional before making decisions about their health or treatment. In a medical emergency, seek immediate medical assistance.